Evaluating cell lines as tumour models by comparison of genomic profiles

Nature Communications

Volumn 4, Issue , 2013, Pages

  Domcke, Silvia ^a,b   Sinha, Rileen ^a   Levine, Douglas A ^a   Sander, Chris ^a   Schultz, Nikolaus ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

CANCER; GENOMICS; REPRODUCTIVE HEALTH; TUMOR; WOMENS HEALTH;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; COPY NUMBER VARIATION; FEMALE; FRAMESHIFT MUTATION; GENETIC SIMILARITY; GENOMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; MISSENSE MUTATION; OVARY CANCER;

CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MODELS, BIOLOGICAL; MULTIGENE FAMILY; MUTATION; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84880291315     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3126     Document Type: Article

References (59)

1. Ertel, A., Verghese, A., Byers, S. W., Ochs, M. & Tozeren, A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol. Cancer 5, 55 (2006).
2. Stein, W. D., Litman, T., Fojo, T. & Bates, S. E. A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res. 64, 2805-2816 (2004). (Pubitemid 38500619)
3. Gillet, J. P. et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl Acad. Sci. USA 108, 18708-18713 (2011).
4. Sandberg, R. & Ernberg, I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc. Natl Acad. Sci. USA 102, 2052-2057 (2005). (Pubitemid 40262010)
5. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
6. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
7. IARC Press. World Cancer Report (eds Boyle, P. & Levin, B.) (IARC Press, Lyon, France, 2008).
8. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA. Cancer. J. Clin. 60, 277-300 (2010).
9. Seidman, J. D. et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23, 41-44 (2004). (Pubitemid 38018236)
10. Gershenson, D. M. et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 108, 361-368 (2006). (Pubitemid 44305678)
11. Bowtell, D. D. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer 10, 803-808 (2010).
12. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719-725 (2011).
13. Berns, E. M. & Bowtell, D. D. The changing view of high-grade serous ovarian cancer. Cancer Res. 72, 2701-2704 (2012).
14. Bast, Jr R. C. & Mills, G. B. Dissecting 'PI3Kness': the complexity of personalized therapy for ovarian cancer. Cancer Discov. 2, 16-18 (2012).
15. Willner, J. et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol. 38, 607-613 (2007). (Pubitemid 46399888)
16. Cho, K. R. & Shih, I. E. M. Ovarian cancer. Annu. Rev. Pathol. 4, 287-313 (2009).
17. Singer, G. et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst. 95, 484-486 (2003). (Pubitemid 36432423)
18. Sieben, N. L. et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 202, 336-340 (2004).
19. Vang, R., Shih, I. E., M. & Kurman, R. J. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol. 16, 267-282 (2009).
20. Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010).
21. Wright, K. et al. beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int. J. Cancer 82, 625-629 (1999). (Pubitemid 29356957)
22. Obata, K. et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58, 2095-2097 (1998). (Pubitemid 28232892)
23. Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681 (2004). (Pubitemid 39446895)
24. Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49-56 (2010).
25. Motoyama, T. Biological characterization including sensitivity to mitomycin C of cultured human ovarian cancers (author's transl). Nihon Sanka Fujinka Gakkai Zasshi 33, 1197-1204 (1981). (Pubitemid 11021474)
26. Motoyama, T. Quantitative analysis on in vitro drug sensitivity of cultured human ovarian cancer cell lines (author's transl). Nihon Sanka Fujinka Gakkai Zasshi 34, 308-314 (1982). (Pubitemid 12079948)
27. van den Berg-Bakker, C. A. et al. Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int. J. Cancer 53, 613-620 (1993). (Pubitemid 23069273)
28. Gilks, C. B. et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum. Pathol. 39, 1239-1251 (2008).
29. Madore, J. et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J. Pathol. 220, 392-400 (2010).
30. Rigakos, G. & Razis, E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 17, 956-962 (2012).
31. Coward, J. et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083-6096 (2011).
32. Taylor, S. A. et al. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo. Gynecol. Oncol. 109, 97-106 (2008).
33. Szotek, P. P. et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl Acad. Sci. USA 103, 11154-11159 (2006). (Pubitemid 44156488)
34. Kulbe, H. et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 72, 66-75 (2012).
35. Leinster, D. A. et al. The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J. Pathol. 227, 136-145 (2012).
36. Galmozzi, E. et al. Exon 3 of the alpha folate receptor gene contains a 50 splice site which confers enhanced ovarian carcinoma specific expression. FEBS Lett. 502, 31-34 (2001). (Pubitemid 32722055)
37. De Cecco, L. et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 23, 8171-8183 (2004). (Pubitemid 39531858)
38. Iorio, E. et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 70, 2126-2135 (2010).
39. Mangiarotti, F. et al. Functional effect of point mutations in the alpha-folate receptor gene of CABA I ovarian carcinoma cells. J. Cell Biochem. 81, 488-498 (2001). (Pubitemid 32405766)
40. Mezzanzanica, D. et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin. Cancer Res. 10, 5202-5214 (2004). (Pubitemid 39099795)
41. Aldovini, D. et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int. J. Cancer 119, 1920-1926 (2006). (Pubitemid 44356852)
42. Gloss, B. S. et al. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett. 318, 76-85 (2012).
43. Macor, P. et al. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res. 66, 3876-3883 (2006).
44. Liu, J. et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod. Pathol. 17, 75-80 (2004). (Pubitemid 41656455)
45. Oda, K. et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 68, 8127-8136 (2008).
46. Han, S. Y. et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 60, 3147-3151 (2000).
47. Oda, K., Stokoe, D., Taketani, Y. & McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65, 10669-10673 (2005). (Pubitemid 41713332)
48. Lukk, M. et al. A global map of human gene expression. Nat. Biotechnol. 28, 322-324 (2010).
49. Wang, H. et al. Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data. BMC 7, 166 (2006).
50. Benard, J. et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 45, 4970-4979 (1985). (Pubitemid 16236181)
51. Wenger, S. L. et al. Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization. Biosci. Rep. 24, 631-639 (2004). (Pubitemid 41297983)
52. Cooke, S. L. et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29, 4905-4913 (2010).
53. Korch, C. et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol. Oncol. 127, 241-248 (2012).
54. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
55. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
56. Ward, J. H. J. Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 48, 236-244 (1963).
57. R Development Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2010).
58. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).
59. Witten, D. M. & Tibshirani, R. sparcl: perform sparse hierarchical clustering and sparse k-means clustering. R package version 1.0.1 (2010). http://www.cran. r-project.org/web/packages/sparcl/index.html.